We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Okyo Pharma Limited | LSE:OKYO | London | Ordinary Share | GG00BD3FV870 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 91.00 | 1.20 | 1.60 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/3/2019 08:12 | #OKYO guys something brewing no trades l2 just moved up again | newtothisgame3 | |
29/3/2019 08:03 | #OKYO up on no trades are the mms aware of news | newtothisgame3 | |
28/3/2019 21:52 | #OKYO #PHARMA 5P … | newtothisgame3 | |
28/3/2019 21:28 | !FOLLOWFEED!YOUTUBEV The price I expect in #OKYO will sound like a Ramp at these current levels but Im hoping for 5p eventually. It may seem a tall order but I think it will be reached when we get positive news. … … … … Standard listing Okyo joined the standard list section of the London Market in July after a reverse takeover into former miner West African Mining. The majority shareholder is the Parmetta Group, which holds the original IP for Chemerin. Picking winners among small biotechs can be difficult for professionals, let alone amateur investors, but the previous successes and track record of management suggest if the compounds are commercial, they will know how to move them forward. At 2.25p, Okyo is valued at £12mln and is much smaller currently than Tiziana (£139mln) but you would not bet against it following a similar path. 14 March 2019 OKYO releases preclinical data on OKYO-0101 at the 14th Congress on Ocular Pharmacology and Therapeutics, 2019 demonstrating its potential to treat dry eye. 07 March 2019 Presentation of Preclinical Data Demonstrating Potential of OKYO-0101 for Dry Eye Treatment | newtothisgame3 | |
07/3/2019 15:18 | OKYO Association for Ocular Pharmacology and Therapeutics (AOPT) … | newtothisgame3 | |
07/3/2019 15:16 | Eye-eye; OKYO rises as it prepares to present pre-clinical data … | newtothisgame3 | |
17/12/2018 11:44 | YEP LOOKING OK | sigora | |
17/12/2018 11:37 | Moving up again here. Need to tighten the spread. | recordz | |
14/12/2018 15:18 | Panic comes to mind | joosepi | |
14/12/2018 14:42 | 11 trades and up 82% jeez | sigora | |
14/12/2018 14:21 | life in the old dog | sigora | |
16/10/2018 15:57 | THE BIG FELLA19 Jul '18 - 16:18 - 14 of 140 0 1 0 I only needed to check who the corporate advisor was to know to give this a wide berth. Good old Beaumont Crusty. What do you get here for near 30 mil mkt cap? I suspect an empty wallet. Which still sums up the investment case here. Avoid like the plague. | the big fella | |
08/10/2018 11:28 | This should get some buying support around 0.70p | elan_1 | |
26/9/2018 21:55 | 1.5 mill delayed print buy. Tomorrow will be smashing | jimduggen | |
26/9/2018 12:23 | Someone paid 2.6 today. Can now buy below 2... Ooops. | babbler | |
26/9/2018 12:22 | See... From almost 30 percent up to red... Ouch. | babbler | |
26/9/2018 11:08 | Gormless Dave here. What a surprise | letmepass | |
26/9/2018 11:02 | rakepat37 Why should this be worth £20 mil valuation ? | dave4545 | |
26/9/2018 10:55 | Is your short burning | rakepat37 | |
26/9/2018 10:49 | Pump and dump. Stay well away from imho | cudmore | |
26/9/2018 10:40 | 5p ? That's 20 million cap, do explain why and I remember the last pump and dump here where the valuation reached silly levels and the price plunged 75% from the highs ? | dave4545 | |
26/9/2018 10:39 | Being ramped again I see... Nice one... For those that want out. | babbler | |
26/9/2018 10:32 | Great opportunity here | letmepass |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions